Back to search

Peptide record

TPDB11528

Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
34 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11528
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia dbACP Antifungipept CAFPdb dbAMP 3.0 ToxinPred 3.0
standard
No
A 34-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF
Physicochemical Analysis
C203H345N53O37S1
ANDCEQHWY
K
4152.37
12.51
15
0
14
+15
8.58
-0.435
80.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
3
I
1
L
13
K
1
M
5
F
2
P
1
S
1
T
0
W
0
Y
4
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 1 K: 13 M: 1 F: 5 P: 2 S: 1 T: 1 W: 0 Y: 0 V: 4
Chemical Descriptors
34
C203H345N53O37S1
4152.37
12.51
+15
8.58
-0.435
Evidence Records 49 records
Evidence 1 Activity

Activity

MIC
Antibacterial
7.7-31 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (
Evidence 2 Activity

Activity

MIC
Antibacterial
7.7 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP DRAMP

Other

active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical
Evidence 3 Activity

Activity

MIC
Antibacterial
3.8 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP DRAMP

Other

inical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae c
Evidence 4 Activity

Activity

MIC
Antibacterial
0.24-3.8 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP DRAMP

Other

213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (
Evidence 5 Activity

Activity

MIC
Antibacterial
1.9 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP DRAMP

Other

te (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical i
Evidence 6 Activity

Activity

MIC
Antibacterial
0.06-3.8 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP DRAMP

Other

53 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilo
Evidence 7 Activity

Activity

MIC
Antibacterial
3.8 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP DRAMP

Other

al isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258
Evidence 8 Activity

Activity

MIC
Antibacterial
40 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP DRAMP

Other

isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM)
Evidence 9 Activity

Activity

MIC
Antibacterial
10-40 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP DRAMP

Other

ve against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM)
Evidence 10 Activity

Activity

MIC
Antibacterial
20-40 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP DRAMP

Other

9 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatop
Evidence 11 Activity

Activity

MIC
Antibacterial
2.5 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP DRAMP

Other

C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM),
Evidence 12 Activity

Activity

MIC
Antibacterial
20 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP DRAMP

Other

C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5
Evidence 13 Activity

Activity

MIC
Antibacterial
1.25 µM

Target

M. canis LABMIC 0401

Source & Reference

dbAMP DRAMP

Other

rapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5 uM) ( Cavalcante et al., 2017 ). Appeared to have p
Evidence 14 Activity

Activity

MIC
Antibacterial
5 µM

Target

T. rubrum LABMIC 0203 or 0204

Source & Reference

dbAMP DRAMP

Other

C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5 uM) ( Cavalcante et al., 2017 ). Appeared to have proinflammatory effect on immune cells such
Evidence 15 Activity

Activity

MIC
Antifungal
7.7-31 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (
Evidence 16 Activity

Activity

MIC
Antifungal
7.7 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical
Evidence 17 Activity

Activity

MIC
Antifungal
3.8 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

inical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae c
Evidence 18 Activity

Activity

MIC
Antifungal
0.24-3.8 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (
Evidence 19 Activity

Activity

MIC
Antifungal
1.9 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

te (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical i
Evidence 20 Activity

Activity

MIC
Antifungal
0.06-3.8 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

53 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilo
Evidence 21 Activity

Activity

MIC
Antifungal
3.8 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

al isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258
Evidence 22 Activity

Activity

MIC
Antifungal
40 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM)
Evidence 23 Activity

Activity

MIC
Antifungal
10-40 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ve against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM)
Evidence 24 Activity

Activity

MIC
Antifungal
20-40 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

9 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatop
Evidence 25 Activity

Activity

MIC
Antifungal
2.5 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM),
Evidence 26 Activity

Activity

MIC
Antifungal
20 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5
Evidence 27 Activity

Activity

MIC
Antifungal
1.25 µM

Target

M. canis LABMIC 0401

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

rapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5 uM) ( Cavalcante et al., 2017 ). Appeared to have p
Evidence 28 Activity

Activity

MIC
Antifungal
5 µM

Target

T. rubrum LABMIC 0203 or 0204

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5 uM) ( Cavalcante et al., 2017 ). Appeared to have proinflammatory effect on immune cells such
Evidence 29 Activity

Activity

MIC
Antiparasitic
7.7-31 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (
Evidence 30 Activity

Activity

MIC
Antiparasitic
7.7 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical
Evidence 31 Activity

Activity

MIC
Antiparasitic
3.8 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

inical isolate (MIC 7.7-31 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae c
Evidence 32 Activity

Activity

MIC
Antiparasitic
0.24-3.8 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

213 and a clinical isolate (MIC 7.7 uM), S. pyogenes clinical isolate (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (
Evidence 33 Activity

Activity

MIC
Antiparasitic
1.9 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

te (MIC 3.8 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical i
Evidence 34 Activity

Activity

MIC
Antiparasitic
0.06-3.8 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

53 and a clinical isolate (MIC 0.24-3.8 uM), K. pneumoniae clinical isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilo
Evidence 35 Activity

Activity

MIC
Antiparasitic
3.8 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

al isolate (MIC 1.9 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.06-3.8 uM), and A. baumannii clinical isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258
Evidence 36 Activity

Activity

MIC
Antiparasitic
40 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP 3.0 DRAMP

Other

isolate (MIC 3.8 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM)
Evidence 37 Activity

Activity

MIC
Antiparasitic
10-40 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP 3.0 DRAMP

Other

ve against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM)
Evidence 38 Activity

Activity

MIC
Antiparasitic
20-40 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP 3.0 DRAMP

Other

9 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatop
Evidence 39 Activity

Activity

MIC
Antiparasitic
2.5 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP 3.0 DRAMP

Other

C. tropicalis LABMIC 0109 (MIC 10-40 uM), C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM),
Evidence 40 Activity

Activity

MIC
Antiparasitic
20 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP 3.0 DRAMP

Other

C. albicans LABMIC 0107 or 0108 (MIC 20-40 uM), C. parapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5
Evidence 41 Activity

Activity

MIC
Antiparasitic
1.25 µM

Target

M. canis LABMIC 0401

Source & Reference

dbAMP 3.0 DRAMP

Other

rapsilosis LABMIC 0113 (MIC 2.5 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5 uM) ( Cavalcante et al., 2017 ). Appeared to have p
Evidence 42 Activity

Activity

MIC
Antiparasitic
5 µM

Target

T. rubrum LABMIC 0203 or 0204

Source & Reference

dbAMP 3.0 DRAMP

Other

C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 1.25 uM), T. rubrum LABMIC 0203 or 0204 (MIC 5 uM) ( Cavalcante et al., 2017 ). Appeared to have proinflammatory effect on immune cells such
Evidence 43 Activity

Activity

10% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
10% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Vipericidins: a novel family of cathelicidin-related peptides from the venom gland of South American pit vipers. | Amino Acids | 2014
Evidence 44 Activity

Activity

7% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
7% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 45 Activity

Activity

33% Hemolysis
Toxicity
400 µM
Hemolytic Cytotoxic
33% Hemolysis | 400 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 46 Activity

Activity

50% Cell death
Toxicity
6.25 µM
Cytotoxic
50% Cell death | 6.25 | µM | target cell: Human fibroblasts

Target

Human fibroblasts

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 47 Activity

Activity

EC50
Toxicity
44.7 µM
Cytotoxic
EC50 | 44.7 | µM | target cell: Monkey kidney epithelial cells LLC-MK2

Target

Monkey kidney epithelial cells LLC-MK2

Source & Reference

NA
DBAASP
Antichagasic effect of crotalicidin, a cathelicidin-like vipericidin, found in Crotalus durissus terrificus rattlesnake's venom gland. | Parasitology | 2017
Evidence 48 Activity

Activity

% Hemolysis
Toxicity
10 %
Hemolytic
Hemolytic_activity: [Ref.25100358] Crotalicidin reached 10% hemolysis at 25 µM. Even so, extrapolation of existing data indicates that 50% hemolysis would be reached at near-millimolar values, which defines an adequate (~2 log) selectivity window.

Target

erythrocytes

Source & Reference

NA
DRAMP
Amino Acids 46:2561-2571(2014)
Evidence 49 Activity

Activity

IC50
Toxicity
3.12 µM
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: 7% and 33% hemolysis at 100 and 400 µM, respectively | Cytotoxicity: MM6: IC50=3.12 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2015 Nov 12 58(21):8553-63.